INTRODUCTION

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting the joints. Despite targeted treatment, inflammation is inadequately controlled in 30% of RA patients, resulting in joint destruction. In the synovium various cell types are central in driving inflammation, among these are T cells and synovial fibroblasts. T cells produce pro-inflammatory cytokines. Cytokines also activate synovial fibroblasts, which subsequently contribute to the

Jaegga and colleagues observed in a murine model of RA that Galectin-3 (Gal-3) expression increased in osteoclasts and T cells, and that Gal-3 targeted fusion proteins were able to suppress osteoclast formation. They hypothesized that Gal-3 may interact with PD-1 and PD-L1 to inhibit PD-1 signaling. We aimed to investigate this hypothesis in human RA tissues and cells.

**Materials and Methods**

We analyzed synovial fluid (SF) and plasma from patients with RA using ELISA to measure PD-1 and Gal-3 levels. Surface Plasmon Resonance and ELISA were used to examine the interaction between PD-1 and Gal-3. Flow cytometry was used to evaluate PD-1, PD-L1, and Gal-3 expression on mononuclear cells from SF and peripheral blood. We also examined the effects of Gal-3 on osteoclast formation using tartrate-resistant acid phosphatase assay.

**Results**

We found high expression of PD-1 and Gal-3 on mononuclear cells, especially from SF. Gal-3 inhibited PD-1 signaling when PD-L1 was present. Furthermore, Gal-3 was observed to inhibit osteoclast formation both directly and through PD-1:PD-L1 inhibition.

**Discussion**

Our findings suggest that high levels of Gal-3 in the complex synovial environment may contribute to impairment of PD-1 signaling and osteoclast activity in RA. Understanding the interaction between Gal-3 and PD-1/PD-L1 may provide new therapeutic targets for the treatment of RA.

**Conclusion**

We conclude that Gal-3 interacts with PD-1 and PD-L1, leading to impaired PD-1 signaling and suppression of osteoclast activity. Further research is needed to explore the clinical implications of these findings.
inflammation and bone destruction by producing matrix metalloproteinases and inducing the expression of receptor activator of nuclear factor kappa-B ligand (RANKL). T cells are thus a central driver of inflammation in RA.

Under normal conditions, T cell activity will decrease when the pathological agent is no longer present. This downregulation is maintained by immune checkpoint inhibitors to prevent autoimmunity. Programmed Death 1 (PD-1) is a glycosylated inhibitory immune checkpoint receptor present on both activated CD4+ and CD8+ T cells. This receptor plays an important role in regulating the immune response and maintaining tolerance. When PD-1 is engaged by its ligands, PD-L1 or PD-L2, the downstream signalling pathway causes downregulation of T cell receptor signalling and hereby inhibits T cell effector functions. This results in a decrease in cytokine production, proliferation and cytolytic function.

In cancer, tumour cells induce expression of PD-L1 and signal through the PD-1 pathway to escape immune surveillance. and PD-1/PD-L1 blockade is considered a breakthrough in cancer treatment, even though some patients experience immune related adverse events (irAE) following treatment. In contrast to cancer, PD-1 signalling is considered to be desirable in autoimmune diseases, like RA and targeting the PD-1 pathway through PD-L1 ameliorates disease activity in a collagen-induced arthritis mouse model. The presence of membrane-bound PD-1 is also associated with a milder course of disease. However, results indicate that PD-1 signalling is downregulated during disease progression. This suggests that PD-1 pathway stimulation is a potential novel treatment for RA patients comparable to a Cytoxic T-lymphocyte-associated protein 4 (CTLA4) analogue, which bind the costimulatory molecules CD80/86 on antigen-presenting cells and thereby inhibits the interaction with CD28 on T cells. The CTLA4 analogue is already implemented in the clinic. Additionally, we previously reported that the PD-1 pathway plays an important role in maintaining bone homeostasis. In RA, CD4+ T cells are known to be key mediators of tissue damage, supporting the close association between the PD-1 system and bone homeostasis.

In contrast, a subset of PD-1hi T helper cells has been identified in seropositive RA and suggested to enable B cell help and thereby promote autoantibody production. These findings highlight the complexity of the PD-1 system.

Immune checkpoint molecules can be regulated at multiple levels. In addition to transcriptional regulation, post-translational modifications such as glycosylation of PD-1 and PD-L1 regulates protein stability and interaction. Furthermore, Galectin-9 (Gal-9) have recently been shown to bind to PD-1 and modulate the pathway by binding to the putative N-linked glycosylation sites (N49, N58, N74 and N116) found on PD-1.

Galectin-3 (Gal-3) is a member of the galectin family of 15 animal lectins with well conserved carbohydrate-recognition domains (CRDs) for β-galactosides. Gal-3 is the sole member of the chimaera-type galectin and it is structurally unique among galectins, consisting of only one CRD linked to an N-terminal peptide domain. Furthermore, Gal-3 stands out among galectins based on a strong association with the pathogenesis of RA, affecting the activity and inflammatory properties of osteoclasts, T cells and stromal cells.

Gal-3 is elevated in plasma from both treatment-naïve patients and patients with long-standing RA. In a CIA rat model, increased levels of Gal-3 were present in the synovium and Gal-3 levels correlated with disease progression. These data correspond with RA patient synovium data, demonstrating increased Gal-3 expression and secretion. The increase in Gal-3 levels has been shown to activate and induce secretion of pro-inflammatory cytokines from synovial fibroblasts. In addition, Gal-3 is involved in cartilage degeneration by inducing Matrix Metalloproteinase 3 expression and some studies also support the idea that Gal-3 is capable of inhibiting osteoclast differentiation as well as promoting osteoclastogenesis, resulting in bone destruction.

Since PD-1 and PD-L1 are post-translationally modified by glycosylation and known to express N-linked glycosylation sites predicted to bind Galactins, we investigated if Gal-3 binds PD-1 or PD-L1 and influence signalling through the PD-1 pathway.

**METHODS**

**2.1 Patients and healthy controls**

RA patient samples from the Inflammation in Arthritis (INART) biobank were randomly chosen for this study. Patient material consisted of plasma, synovial fluid (SF) as well as fibroblast-like synoviocytes (FLS), and mononuclear cells from peripheral blood (PBMCs) and SF (SPMCs). All patients were chronic RA patients (n = 41, age: 52.3 ± 4.51, sex [female%]: 67.5%) and samples were collected when patients presented with disease flare. Healthy control (HC, n = 15, age: 40.5 ± 7.76, sex [female%]: 53.3%) samples were provided by the Danish blood bank.

**2.2 ELISA**

Levels of sPD-1 and Gal-3 were measured by sandwich ELISA (PD-1: R&D systems, DY1086, Gal-3: R&D systems, DGAL30). Samples were run in duplicates. In the
PD-1 ELISA, bovine, goat and mouse IgG was added to the samples to block heterophilic antibodies against animal proteins. Optical Density (OD) values were read in a microplate reader at 450nm with a 570nm reference.

A combinatorial ELISA setup was used to investigate Gal-3’s binding of sPD-1. In brief, wells were coated with rhGal-3 (1 μg/mL) (R&D systems, DGAL30). Detection was done with PD-1 detection antibody from the PD-1 ELISA kit (PD-1: &D systems, DY1086). Samples included RA SF, RA plasma and HC plasma.

2.3 Surface plasmon resonance

Surface Plasmon Resonance (SPR) was performed on the Biacore 3000 instrument (Biacore, Molecular Interactions Core Facility, AU). Binding was investigated between the recombinant human proteins; rhGal-3 (E.coli produced as described by Salomonsson et al. kindly provided by Prof. Hakon Leffler), rhPD-1 (R&D systems, 1086-PD) and rhPD-L1 (R&D systems, 156-B7-100). PD-1 or PD-L1 was immobilized on the surface by protein G coupling. Increasing concentrations of rhGal-3 was injected in the flow cell. Lactose was used as control to inhibit Gal-3 binding.

The two-dimensional fits were made on the MATLAB 2012a platform (Mathworks) using the fitting tool EVIDFIT version 3 software created by Peter Schuck as previously described. In brief, input values matched the start and end injection time and included concentrations spanning from 62.5 nM to 500 nM for Gal-3 to PD-1 and from 15.6 nM to 4000 nM for Gal-3 to PD-L1. The association phase was fitted from t = ‘injection start’ plus 1 s to t = ‘injection end’ minus 5 s. Dissociation phase was fitted from t = ‘injection end’ plus 5 s to t = ‘injection end’ plus 200–300 s. The operator-set boundaries for the distributions were uniformly set to limit KD values in the interval from 10^-9 to 10^-2 M, and koff values in the interval from 10^-5 to 10^1 s^-1 to ensure comparable and best quality fits reflected in a high signal to rmsd ratio. The distribution P (k_a, K_A) is calculated using the discretization of the equation:

$$ R_{total} = \int_{K_{Amin}}^{K_{Amax}} \int_{k_{amin}}^{k_{amax}} R(k_a, K_A, C_{analyte}) P(k_a, K_A) dk_a dK_A $$

in a logarithmic grid of $k_a$, $K_A$, i) values with 21 and 18 grid points distributed on each axis, respectively. This was done through a global fit to association and dissociation traces at the above-mentioned analyte concentrations. Tikhonov regularization was used as described by Zhao et al. at a confidence level of $P$ = .95 to determine the most parsimonious distribution that is consistent with the data, showing only features that are essential to fit the data.

2.4 Cell stimulation assays

RA SFMCs, RA and HC PBMCs were stimulated for 24 h with anti-CD3 (1 μg/mL, Okt3, Peprotech, 05121-20-100) and anti-CD28 (0.5 μg/mL, BD, 555725) prior to flowcytometric assessment of PD-1 and Gal-3 expression.

To determine intracellular IL-2 levels, HC PBMCs were stimulated with phthoehemagglutinin (PHA, 5 μg/mL, A10978) for 48 h, then rested overnight in serum free media. CD4+ cells were isolated by negative selection (EasySep™ Human CD4+ T Cell Isolation Kit, StemCell Technologies, 17952). CD4+ T cells were subsequently stimulated with anti-CD3/anti-CD28 and given either of the following treatment for 4 h: rhPD-1, rhPD-L1, rhGal-3, rhGal-3 + rhPD-1 or rhGal-3 + rhPD-L1 (all 1 μg/mL). Brefeldin A (BFA) (10 μg/mL, Sigma, B7651-5 mg) was added to inhibit intracellular protein transport.

Fibroblast-like synoviocytes (FLS) were cultured from RA SFMC as previously described. FLS at passage 4–5 were cultured in a 6-well plate (30000 cells/well). When confluent, cells were cultured with Tumour Necrosis Factor (TNF)-α (10 ng/mL) or interferon (IFN)-γ (10 ng/mL) for 48 h and stained for flow cytometry. Additionally, FLS were used in a stimulation assay. FLS were seeded out in a 96-well plate (10000 cells/well). Once confluent cells were stimulated for 48 h with IFN-γ (10 ng/mL). Gal-3 was measured in the supernatant (R&D systems, DGAL30).

RA SFMCs were also used for osteoclast differentiation. Every 3 days culture medium was changed and supplemented with rh Receptor activator of nuclear factor kappa-B ligand (RANKL) (50ng/mL, Abcam, ab157289) and rh Macrophage Colony-stimulating Factor (M-CSF) (25ng/mL, Peprotech, 300–25). When media was changed the same treatment combinations of PD-1, PD-L1 and Gal-3 as described for HC PBMCs were administered. As a measure of osteoclast activity, levels of Tartrate-resistant acid phosphatase (TRAP) were measured in supernatants from day 21 using a commercially available kit (AK04, B-Bridge International, Inc.).

2.5 Flow cytometry

PBMCs and SFMCs were stained for flow cytometry using anti-CD4 APC (clone: RPA-T4, BioLegend, 300 552), anti-CD8 AF700 (clone: RPA-T8, BD, 56–0088-41), anti-CD25 PerCP-Cy5.5 (clone: M-A251, BD, 560503), anti-PD-1 AF488 (clone: EH12.2H7, BioLegend, 329936), anti-Gal-3 PE (clone: Gal397, BD, 126706), anti-IL-2 PECY7 (clone:
MQ1 17H12, BD, 560707) and nIR Live/Dead marker (Thermo Fisher, L34976), all at recommended concentrations. For intracellular staining the True-Nuclear™ Transcription Factor Buffer Set (Biolegend, 424401) was used.

FLS were stained for flow cytometry using anti-CD90 BV605 (clone: SE10, BioLegend, 328128), anti-ICAM BV421 (clone: HA58, BD, 564077) and anti-PD-L1 PECy7 (clone: MIH3, BioLegend, 374506) as well as intracellular: anti-Gal-3 PECF594 (clone: B2C10, BD, 565682).

Flow cytometric data acquisition was performed using the NovoCyte Quanteon® (ACEA Bioscience, San Diego, CA, USA) and flow cytometric analysis were performed in FlowJo™ 10.7.1. Gating was performed by including live, single cells. Additionally, gating was performed using fluorescence minus one (FMO) control (Figure S1, Figure S3+c).

### 2.6 Immunofluorescence staining of synovial membranes

Formalin fixed, paraffin embedded sections of human RA synovial membranes were single-stained for either Gal-3 or PD-1. First, tissue sections were deparaffinized and rehydrated in Xylene and decreasing concentrations of ethanol, before demasking proteins in near-boiling Target Retrieval buffer (DAKO, S2369, pH 6). Tissue sections were blocked in 10% donkey serum and single-stained for PD-1 (20 μg/mL murine anti-human PD-1 antibody (clone: NAT105, Abcam, ab52587), secondary antibody: AF488 Donkey anti-mouse IgG (Jackson ImmunoResearch, 715-546-151) or Gal-3 (10 μg/mL rat anti-human Galectin-3 antibody (clone: M3/38, MABT51)), secondary antibody AF488 AffiniPure Donkey anti-rat IgG (Jackson ImmunoResearch, 712-546-153). For mounting and DAPI staining mounting media was applied (Invitrogen, P36941). Stained synovial membranes were examined using a Zeiss LSM800 confocal microscope. ImageJ was used to collect the signal from the z-stacks obtained on the microscope into one image with maximum signal of the section.

### 2.7 Study approval

Human clinical studies were conducted in accordance with the Helsinki declaration. Informed written content was provided from all patients participating in the study. The INART biobank is approved by the ethical committee and the Danish Data Protection Agency (20121329). Plasma from anonymous HCs was obtained from the Danish blood bank.

### 2.8 Statistics

Statistical analysis was performed using GraphPad Prism 9.1 (GraphPad Software).

Statistical analysis consisted of parametric tests (paired/unpaired t-tests) when data followed Gaussian distribution. If data did not meet Gaussian distribution criteria even after log-transformation, non-parametric tests were applied (Wilcoxon signed rank test (paired) or Mann–Whitney test (unpaired)). Graph whiskers represent standard deviation (SD). P-values ≤0.05 were considered statistically significant (α = 0.05). When describing data following Gaussian distribution mean values ±95% confidence intervals were stated, while data not following Gaussian distribution were expressed as median (Interquartile range [IQR], Q1-Q3).

### 3 RESULTS

#### 3.1 PD-1 and Gal-3 are highly expressed in the inflamed joint in RA

Levels of sPD-1 were significantly increased in RA SF compared to RA plasma. Further, RA plasma PD-1 levels were increased compared to HC plasma(Figure 1A). As for sPD-1, levels of Gal-3 were also increased in RA SF compared to RA plasma. Gal-3 plasma levels did not differ significantly between RA patients and HC (Figure 1B).

To further characterize the presence of PD-1 and Gal-3 in SF, we examined cellular expression on RA SFMCs, comparing to RA and HC PBMCs. Significantly more CD4+ T cells expressed PD-1+ in RA SFMCs compared to RA PBMCs and HC PBMCs (P < .01, Figure 1C). Upon stimulation, PD-1 expression increased significantly in all cell groups, with levels remaining highest in RA SFMCs after stimulation (Figure 1C). Expression of PD-1 among the CD4+ T cells did not differ between HC and RA PBMCs, neither before, nor after stimulation. As for PD-1, CD4+ T cells from unstimulated RA SFMCs expressed higher levels of Gal-3 compared to RA PBMCs. Upon stimulation, Gal-3 expression did not change significantly in any cell group. Expression of Gal-3 did not differ between HC and RA PBMCs (Figure 1D). When examining CD4+ T cells double positive for PD-1 and Gal-3, these were more abundant in RA SFMCs compared to RA PBMCs and HC (P < .05). Upon stimulation, the percentage of PD-1+ Gal-3+ expressing CD4+ T cells increased in all cell groups (Figure 1E). We further confirmed the presence of both PD-1 and Gal-3 in the RA synovium, by immunofluorescence staining of the synovial membrane. Both PD-1 and Gal-3 were expressed widely in the synovial membrane tissue sections; however, Gal-3 expression was more pronounced (Figure 1F).
3.2 | Stimulating Fibroblast-Like Synoviocytes upregulates expression of PD-L1 and facilitates Gal-3 secretion

Next, we characterized the expression of PD-L1 and Gal-3 in inflammatory FLS defined as CD90+ICAM+. Stimulating FLS with either TNF-α or IFN-γ induced close to 100% ICAM-positive cells, supporting an activated state (Figure S3). Stimulation resulted in significantly higher percentage of PD-L1+ expressing FLS (Figure 2A), whereas stimulating cells with TNF-α induced a decreased percentage of Gal-3 expressing cells (Figure 2B). IFN-γ induced PD-L1 expression in nearly all cells, which was also demonstrated in the t-distributed stochastic neighbour embedding (t-SNE) plot (Figure 2E). The percentage of Gal-3+ cells was unaffected by IFN-γ stimulation (Figure 2B). Evaluating PD-L1+Gal-3+ inflammatory FLS, PD-L1 MFI was significantly increased by IFN-γ stimulation and Gal-3 MFI was significantly decreased by both stimulations (Figure 2c+d). The decrease in intracellular Gal-3 levels upon stimulation was also visualized in the t-SNE plot (Figure 2E).

As intracellular Gal-3 decreased upon IFN-γ stimulation, we investigated if levels of secreted Gal-3 were affected by stimulation. Upon stimulation, Gal-3 in the supernatant increased significantly (Figure 2F). These results indicate how inflammatory FLS contribute to the higher extracellular levels of Gal-3 observed in synovial fluid from RA patients (Figure 1B).

3.3 | Gal-3 binds PD-1 and PD-L1

To establish the binding capacity between PD-1 and Gal-3 we used SPR. Increasing concentrations of rhGal-3 was subjected to the rhPD-1-coupled chip surface,
which resulted in an increased mass on the chip surface measured in response units (RU), supporting binding between PD-1 and Gal-3 (Figure 3A). Quantitative evaluation of possible heterogenous binding was done using EVILFIT analysis,\textsuperscript{42,43} which calculates the minimal distribution in binding kinetics for heterogeneous ligand interactions (Figure S2). The most abundant interaction between rhGal-3 and rhPD-1 had a $K_D$ of $10^{-6}$.

For rhPD-L1 the $K_D$ value was estimated to be approximately $10^{-5}$ (Figure S2). From the 2D-binding analysis we observed that the major population contributing to binding between Gal-3 and PD-1 had a slow dissociation rate and, therefore, would retain complex formation for an extended period of time ($k_{off} = 10^{-2.5}$ s$^{-1}$). The opposite was observed between Gal-3 and PD-L1 with the major contributor of binding having a dissociation rate of ($k_{off} = 10^{-0.5}$ s$^{-1}$). Still, both interactions showed multiple binding populations suggesting a that complex formation is not well-described by a simple 1:1 interaction. Furthermore, addition of lactose was able to inhibit the interaction between rhGal-3 and rhPD-L1 in a dose dependent manner (Figure S2).

After demonstrating Gal-3 interaction with PD-1 and PD-L1 in vitro, we next examined whether rhGal-3 could bind sPD-1 from patient plasma and SF. The binding was confirmed using a combinatorial ELISA consisting of a Gal-3 protein coat and detecting bound PD-1 with an anti-PD-1 detection antibody. Furthermore, higher levels of sPD-1 binding to Gal-3 was seen in RA SF, compared to RA and healthy plasma, demonstrating that PD-1 from the inflamed environment still contained Gal-3 binding sites. (Figure 3B).

### 3.4 Galectin-3 inhibits the anti-inflammatory function of PD-1 signalling in RA patients

We next investigated the potential effect of Gal-3 interacting with PD-1 upon T cell activation. We used intracellular
**FIGURE 3** Binding of Gal-3 to PD-1 and PD-L1. A, Sensorgram of Gal-3 interaction with PD-1 coupled to the chip. Concentrations of Gal-3 in buffer ranges from 125-4000 nM. Binding visualized by rise in signal (response units, RU). Gal-3 is capable of binding PD-1. B, Combinatorial ELISA. Levels of soluble PD-1 in RA SF (n = 25) and plasma and HC plasma (n = 7, each) capable of binding immobilized rhGal-3. Levels expressed as blanked OD values. Significantly higher PD-1 levels in SF detected by rhGal-3 compared to RA plasma and HC plasma.

**FIGURE 4** Functions of Gal-3 on cellular inflammation (IL-2) and the PD-1 signalling axis. A, Levels of IL-2 evaluated by MFI in CD4+ T cells treated with rhPD-L1, rhGal-3 or rhGal-3 combined with rhPD-L1. IL-2 MFI expressed as ratios calculated as: Treated / NT. rhPD-L1 slightly decreased intracellular IL-2 levels, while rhGal-3 significantly decreased intracellular IL-2 levels. B, t-SNE plot. Horizontal labels represent flow cytometric markers, whereas vertical labels represent cellular treatments before flow cytometry. IL-2 levels are downregulated in a specific cellular subset in CD4+ T cells treated with rhGal-3 or rhPD-L1 only, whereas the population reappears when cells are treated with both rhPD-L1 and rhGal-3 in combination (black arrows). N = 3.
IL-2 as a measure of T cell activation and reduced PD-1 signalling. Upon stimulation of CD4+ T cells, intracellular IL-2 levels decreased 33.75 ± 12.14% in the presence of rhPD-L1 compared to untreated CD4+ T cells. When adding rhGal-3 to the culture levels decreased significantly with 63.99 ± 13.72%. However, combining rhGal-3 and rhPD-L1 reversed the effect and caused no decrease in IL-2 (Figure 4A). This effect was also visualized in the t-SNE plot, where levels of IL-2 in a specific subset decreases in cells treated with rhGal-3 or rhPD-L1 (Figure 4B). No effect was seen of rhPD-1 (Figure S3).

3.5 | Galectin-3 facilitates osteoclast formation while PD-L1 reduces osteoclast formation in RA patients

Joint and bone destruction are severe complications in RA and both PD-1 and Gal-3 are linked to the activity of osteoclasts. Hence, we investigated if Gal-3 interacting with the PD-1 pathway could influence osteoclast formation. Adding rhPD-L1 to RA SFMC osteoclast cultures slightly decreased TRAP activity after 21 days of culture, while rhGal-3 significantly increases TRAP activity. Combining rhGal-3 with rhPD-L1 in 1:1 stoichiometry demonstrated how rhPD-L1 plays a role in decreasing TRAP activity; however, rhPD-L1 was not able to significantly counteract the stimulatory effects of rhGal-3 in regard to osteoclast formation (Figure 5, Figure S4).

4 | DISCUSSION

Here, we report that Gal-3 binds to PD-1 and PD-L1 and that this interaction plays a role in inhibiting PD-1 signalling in RA Th cells and osteoclasts. Gal-3 and PD-1 were present in high levels in the inflamed RA joint, both as soluble forms and expressed by cells. Upon stimulation of T cells, PD-1 expression increased, whereas expression of Gal-3 remained unchanged. We also confirmed the interaction between PD-1 and Gal-3 in an inflammatory setting, capturing soluble PD-1 from the synovial fluid by Gal-3. These data are supportive of an interaction between PD-1 and Gal-3 in the inflamed synovium and suggest that the Gal-3 N-glycosylation binding sites on PD-1 are not changed in the highly inflamed microenvironment even though glycosylation is known to be modulated in this environment.

Fibroblasts are central mediators of the inflammation in the RA joint, and we suggest these cells, as a major source of extracellular Gal-3. This is supported by IFN-γ stimulation where intracellular Gal-3 decreased in concordance with increasing Gal-3 secretion. Decreased intracellular Gal-3 upon IFN-γ stimulation is previously reported. Selectively targeting Gal-3 s CRD was reported to decrease FLS and osteoclast activity in RA, and the present study adds a possible molecular explanation to the reduction in inflammation seen with a specific Gal-3 inhibitor. Treatment with the Gal-3 inhibitor could potentially block the interaction between Gal-3 and PD-1/
PD-L1 and hereby decrease both T cell and osteoclast activation.

We further highlighted the functional significance of Gal-3, influencing the PD-1 pathway. Adding Gal-3 to CD4 T cells cultured in the presence of rhPD-L1, significantly increased intracellular IL-2 levels, suggesting Gal-3 can reverse the inhibition mediated by the PD-1 pathway. The precise mechanism of this reversed inhibition remains to be elucidated, but a stimulatory role of Gal-3 has previously been described in IL-17 producing T cells from a RA mouse model.28 Whether this effect is due to inhibition of immune checkpoint inhibitor receptors has not earlier been described. Another feature to consider is that the effect of Gal-3 seems to be dependent on the microenvironment, as well as type of disease and potentially also on the degree of ligand-induced multimerization of Gal-3. In RA, Gal-3 is associated with disease severity and inflammation, whereas the opposite effect has been observed in multiple types of cancer. In cancer, Gal-3 has been shown to have immunosuppressive effects, when present in the tumour microenvironment, thereby enabling the tumour to escape the immune system.46,47 Multimerization can be induced in environments with high levels of Gal-3 ligands, for instance the high concentrations of PD-1 in RA synovium. This is supported by the slow dissociation rate for Gal-3 binding to PD-1 demonstrated by SPR. Multimerization will result in high local levels of Gal-3, but also in increased functional affinity through increased avidity, which further facilitates the interaction between Gal-3 and PD-1 or PD-L1. The interaction could potentially hinder PD-1:PD-L1 interaction sterically in RA.

On the contrary, low sPD-1 levels have been observed in different types of cancer,48 thus PD-1 is not available as a Gal-3 ligand to induce multimerization. Gal-3 could thus be in a monomeric form in certain types of cancer, explaining the different effects of Gal-3 in RA and cancer.

This corresponds with studies in breast cancer, where a germline mutation in Gal-3 abrogated formation of multimeric Gal-3, causing subjects to be more prone to develop cancer.49,50 Therefore, monomeric Gal-3 might play a role in the immunosuppression seen in some cancers. In this study Gal-3 could also be in a monomeric form, when administered alone, since Gal-3 without ligand are known to behave as a monomer up to a concentration of 100 μM.51 In contrast, multimeric Gal-3 dominates when Gal-3 is administered in combination with a ligand, for example PD-L1, resulting in a more pro-inflammatory effect of Gal-3, through inhibition of PD-1 signalling. Furthermore, $K_d$ for Gal-3 s binding to PD-1 was estimated to be 1 μM, meaning that in the presence of high levels of Gal-3 ligand, here PD-1, the multimerization limit for Gal-3 is decreased by at least a factor 100. Thus making, Gal-3 a local antagonist of PD-1 signalling in the synovium of RA patients, meaning Gal-3 is not desirable in RA. Elucidating whether the potential diversity in Gal-3’s function is dependent on its form is important knowledge when developing new treatment options in RA – as well as in different types of cancer.

A further addition to the diversity of Gal-3’s function is the many factors contributing to the complexity in RA synovium. One of these is Galectin-3 Binding Protein (G3BP). G3BP binds galectins such as Gal-3.26,52 Since G3BP is also a highly glycosylated protein, elucidating the potential effect of G3BP on the PD-1:Gal-3 interaction is highly relevant, but beyond the scope of this study.

Finally, we provide evidence supporting that Gal-3 has a direct stimulatory effect on osteoclasts, thereby facilitating bone erosions. Gal-3 also play a role in preventing PD-L1 from decreasing osteoclast activity. These results support the hypothesis that PD-L1 and Gal-3 can interact and repel each other’s effect. This effect of Gal-3 is supported by studies performed in mice.28,30 The effect of PD-L1 is also supported by the literature demonstrating the importance of the PD-1 axis in maintaining bone homeostasis.16

5 | CONCLUSIONS
Collectively, this study suggests that Gal-3 binds to PD-1 and PD-L1. Presence of PD-1 and Gal-3 were demonstrated on mononuclear cells in blood and synovial fluid. The effects of Gal-3 differed between microenvironments, but when PD-L1 was present, Gal-3 had an inhibitory effect on PD-1 signalling. Furthermore, a sole pro-inflammatory and osteoclastogenic role of Gal-3 was observed in osteoclast cultures, both directly by osteoclast formation, but also though the PD-1 pathway. Thus, the main effect of Gal-3 on the PD-1 signalling axis are proposed to be inhibitory, meaning high Gal-3 levels in the complex synovial microenvironment are not desired in RA.

AUTHOR CONTRIBUTIONS
Kathrine Pedersen involved in formal analysis, investigation, writing the original draft editing and funding acquisition. Morten Aagaard Nielsen involved in conceptualization, methodology and original draft editing. Kristian Juul-Madsen involved in formal analysis and original draft editing. Malene Hvid involved in methodology and original draft editing. Bent Deleuran involved in conceptualization, supervision, project administration and original draft editing. Stinne Ravn Greisen involved in conceptualization, methodology, original draft editing and supervision.
ACKNOWLEDGMENTS
We wish to thank the FACS Core Facility and staff for help with flow cytometry. We also want to thank AU Imaging Core for help with confocal microscopy. Thanks to Jakob Hauge Mikkelsen and the Biacore Facility for help with SPR.

FUNDING INFORMATION
The work was funded by Aase and Ejner Danielsens Foundation, Denmark (20-10-0363).

CONFLICT OF INTEREST
Authors have no disclosures or competing interests.

DATA AVAILABILITY STATEMENT
Data available on request from the authors.

ORCID
Kathrine Pedersen https://orcid.org/0000-0002-3058-7960
Stinne Ravn Greisen https://orcid.org/0000-0003-2922-3307

REFERENCES


**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Pedersen K, Nielsen MA, Juul-Madsen K, Hvid M, Deleuran B, Greisen SR. Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid Arthritis. *Scand J Immunol.* 2023;97:e13245. doi:10.1111/sji.13245